Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
| Status: | Recruiting |
|---|---|
| Conditions: | Gastrointestinal, Gastrointestinal, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any - 40 |
| Updated: | 4/2/2016 |
| Start Date: | July 2010 |
The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The purpose of this study is twofold. First, is to determine whether vancomycin is effective
in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and
if so, by what mechanism. Secondly, to characterize human intestinal microbial communities
and their interactions with the host.
in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and
if so, by what mechanism. Secondly, to characterize human intestinal microbial communities
and their interactions with the host.
Inclusion Criteria:
- Persons who have primary sclerosing cholangitis, biliary atresia, a chronic
intestinal disorder or who are undergoing upper or lower endoscopy.
- Persons who have primary sclerosing cholangitis or biliary atresia who are good
candidates for vancomycin therapy.
Exclusion Criteria:
- Patients that have taken antibiotics and/or immunomodulators within the last 3 months
will be excluded as this will alter the original bacterial flora.
- Females who are pregnant may not participate.
We found this trial at
1
site
Click here to add this to my saved trials
